DCDaisy Chen

Daisy Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daisy Chen has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of plasmodium SEY1, an essential dynamin-like GTPase and potential anti-malarial druggable target

    by Krypton Carolino, James Blauwkamp, Alex Bottome, Sonja Ghidelli-Disse, Mariana Laureano De Souza, Elizabeth K. Harmon, Amy DeRocher, Alexander A. Morano, Daisy Chen, Madeline Farringer, et al.

    In some species, SEY1 is a predicted essential dynamin-like GTPase that is implicated in homotypic fusion of endoplasmic reticulum membranes. SEY1 family members are conserved among eukaryotic pathogens, but they show minimal similarity to human atlastins. Here, we characterize Plasmodium SEY1 proteins. Through conditional knockdown and epitope tagging studies in P. falciparum, we demonstrate that SEY1 is essential, localizes within the endoplasmic reticulum, and its disruption leads to defects in endoplasmic reticulum morphology. We show that P. vivax SEY1 can be recombinantly expressed as a soluble truncated isoform. This protein maintains its catalytic activity and ability to dimerize. It also possesses a moderate K d for GTP and is amenable to high throughput inhibition studies. Our data show that SEY1 is a new and attractive druggable and assayable target that is conserved across Plasmodium species.

  • Top Cited Papers
    Open Access

    In vivo screen of Plasmodium targets for mosquito-based malaria control

    by Alexandra S. Probst, Douglas G. Paton, Federico Appetecchia, Selina Bopp, Kelsey L. Adams, Tasneem A. Rinvee, Sovitj Pou, Rolf Winter, Esrah W. Du, Sabrina Yahiya, et al.

    The decline in malaria deaths has recently stalled owing to several factors, including the widespread resistance of Anopheles vectors to the insecticides used in long-lasting insecticide-treated nets (LLINs)1,2. One way to mitigate insecticide resistance is to directly kill parasites during their mosquito-stage of development by incorporating antiparasitic compounds into LLINs. This strategy can prevent onward parasite transmission even when insecticides lose efficacy3,4. Here, we performed an in vivo screen of compounds against the mosquito stages of Plasmodium falciparum development. Of the 81 compounds tested, which spanned 28 distinct modes of action, 22 were active against early parasite stages in the mosquito midgut lumen, which in turn prevented establishment of infection. Medicinal chemistry was then used to improve antiparasitic activity of the top hits from the screen. We generated several endochin-like quinolones (ELQs) that inhibited the P. falciparum cytochrome bc 1 complex (CytB). Two lead compounds that targeted separate sites in CytB (Qo and Qi) showed potent, long-lasting and stable activity when incorporated and/or extruded into bed net-like polyethylene films. ELQ activity was fully preserved in insecticide-resistant mosquitoes, and parasites resistant to these compounds had impaired development at the mosquito stage. These data demonstrate the promise of incorporating ELQ compounds into LLINs to counteract insecticide resistance and to reduce malaria transmission.


  • Open Access

    Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance

    by Madeline R. Luth, Karla P. Godinez-Macias, Daisy Chen, John Okombo, Vandana Thathy, Xiu Cheng, Sindhu Daggupati, Heledd Davies, Satish K. Dhingra, Jan M. Economy, et al.

    Surveillance of drug resistance and the discovery of novel targets—key objectives in the fight against malaria—rely on identifying resistance-conferring mutations in Plasmodium parasites. Current approaches, while successful, require laborious experimentation or large sample sizes. To elucidate shared determinants of antimalarial resistance that can empower in silico inference, we examined the genomes of 724 Plasmodium falciparum clones, each selected in vitro for resistance to one of 118 compounds. We identified 1448 variants in 128 recurrently mutated genes, including drivers of antimalarial multidrug resistance. In contrast to naturally occurring variants, those selected in vitro are more likely to be missense or frameshift, involve bulky substitutions, and occur in conserved, ordered protein domains. Collectively, our dataset reveals mutation features that predict drug resistance in eukaryotic pathogens.


  • Open Access

    Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action

    by Elizabeth Winzeler, Krypton Carolino, Mariana Laureano De Souza, Daisy Chen, Jean-Claude Farre, James Blauwkamp, Sabrina Absalon, Sonja Ghidelli-Disse, Alexander Morano, Jeffrey Dvorin, et al.

    The precise mode of action of ganaplacide (KAF156), a phase III antimalarial candidate, remains elusive. Here we employ omics-based methods with the closely related chemical analog, GNF179, to search for potential Plasmodium targets. Ranking potential targets derived from chemical genetics and proteomic affinity chromatography methodologies identifies SEY1, or Synthetic Enhancement of YOP1, which is predicted to encode an essential dynamin-like GTPase implicated in homotypic fusion of endoplasmic reticulum (ER) membranes. We demonstrate that GNF179 decreases Plasmodium SEY1 melting temperature. We further show that GNF179 binds to recombinant Plasmodium SEY1 and subsequently inhibits its GTPase activity, which is required for maintaining ER architecture. Using ultrastructure expansion microscopy, we find GNF179 treatment changes parasite ER and Golgi morphology. We also confirm that SEY1 is an essential gene in P. falciparum. These data suggest that SEY1 may contribute to the mechanism of action of imidazolopiperazines and is a new and attractive druggable target.


  • Open Access

    Community diversity is associated with intra-species genetic diversity and gene loss in the human gut microbiome

    by Naïma Jesse Madi, Daisy Chen, Richard Wolff, B Jesse Shapiro, Nandita R Garud

    The human gut microbiome contains a diversity of microbial species that varies in composition over time and across individuals. These species (and strains within species) can migrate across hosts and evolve by mutation and recombination within hosts. How the ecological process of community assembly interacts with intra-species diversity and evolutionary change is a longstanding question. Two contrasting hypotheses have been proposed based on ecological observations and theory: Diversity Begets Diversity (DBD), in which taxa tend to become more diverse in already diverse communities, and Ecological Controls (EC), in which higher community diversity impedes diversification within taxa. Previously, using 16S rRNA gene amplicon data across a range of environments, we showed a generally positive relationship between taxa diversity and community diversity at higher taxonomic levels, consistent with the predictions of DBD (Madi et al., 2020). However, this positive 'diversity slope' reaches a plateau at high levels of community diversity. Here we show that this general pattern holds at much finer genetic resolution, by analyzing intra-species strain and nucleotide variation in static and temporally sampled shotgun-sequenced fecal metagenomes from cohorts of healthy human hosts. We find that both intra-species polymorphism and strain number are positively correlated with community Shannon diversity. This trend is consistent with DBD, although we cannot exclude abiotic drivers of diversity. Shannon diversity is also predictive of increases in polymorphism over time scales up to ~4-6 months, after which the diversity slope flattens and then becomes negative-consistent with DBD eventually giving way to EC. Also supporting a complex mixture of DBD and EC, the number of strains per focal species is positively associated with Shannon diversity but negatively associated with richness. Finally, we show that higher community diversity predicts gene loss in a focal species at a future time point. This observation is broadly consistent with the Black Queen Hypothesis, which posits that genes with functions provided by the community are less likely to be retained in a focal species' genome. Together, our results show that a mixture of DBD, EC, and Black Queen may operate simultaneously in the human gut microbiome, adding to a growing body of evidence that these eco-evolutionary processes are key drivers of biodiversity and ecosystem function.